Immunotherapy poses tough questions for legacy players

Advances in immunotherapy, which could extend the lives of
people with cancers such as asbestos-related mesothelioma, could
lead to a problem for run-off players, a legacy conference has been
told.
Treatment breakthroughs - allowing the body's own immune
system to fight cancerous cells - could see mesothelioma become a
"manageable yet chronic" condition, said Ian Harvey, head
of claims strategy for run-off outsourcing company Pro, citing the
view of at least one eminent chest physician in the UK